Use of inotropes and vasopressor agents in critically ill patients

Mansoor N Bangash, Ming-Li Kong and Rupert M Pearse

William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, London, UK

Inotropes and vasopressors are biologically and clinically important compounds that originate from different pharmacological groups and act at some of the most fundamental receptor and signal transduction systems in the body. More than 20 such agents are in common clinical use, yet few reviews of their pharmacology exist outside of physiology and pharmacology textbooks. Despite widespread use in critically ill patients, understanding of the clinical effects of these drugs in pathological states is poor. The purpose of this article is to describe the pharmacology and clinical applications of inotropic and vasopressor agents in critically ill patients.

Introduction

Inotropes are agents administered to increase myocardial contractility whereas vasopressor agents are administered to increase vascular tone. The use of these potent agents is largely confined to critically ill patients with profound hemodynamic impairment such that tissue blood flow is not sufficient to meet metabolic requirements. Examples include patients with severe heart failure and septic or cardiogenic shock, as well as patients undergoing major surgery and victims of major trauma. They are generally administered via a large central vein and, in some specific situations, via a peripheral vein. These agents have a diverse range of actions including metabolic and immune effects, many of which are poorly understood. The objective of this review is to describe the underlying cardiovascular mechanisms that clinicians seek to influence through the use of inotropic agents, to describe the basic pharmacology of those drugs in common use and, finally, to explore the evidence base for specific approaches to inotrope and vasopressor therapy in clinical practice. As many of the commonly used agents exert both inotropic and vasopressor effects, the term ‘inotrope’ will be generally used in this review to describe agents with a spectrum of actions.

The physiological basis for the actions of inotropic agents

Myocyte excitation and contraction. Cardiac muscle fibres contract through the sliding filament mechanism. Actin and myosin filaments are propelled past each other through repeated cross-bridge linking and unlinking. Each cardiac action potential results in the opening of voltage-gated myocyte calcium channels and a rise in intracellular calcium concentration ([Ca\(^{2+}\)]\(_{i}\)). This triggers a further release of calcium from the sarcoplasmic reticulum, which accounts for around three quarters of the total increase in [Ca\(^{2+}\)]\(_{i}\) (Levick, 2003) (Figure 1). At rest, tropomyosin blocks the actin-binding site, preventing engagement of myosin heads. Calcium ions bind to troponin C within the troponin complex, displacing tropomyosin. This exposes the actin-binding site, allowing cross-bridge formation with myosin heads. The orientation of the myosin head changes, causing filaments to slide past each other in an ATP-dependent process. At the end of the action potential, during repolarization, calcium ions are pumped back into the sarcoplasmic reticulum, allowing myocardial relaxation.

Force and rate of myocardial contraction: inotropy and chronotropy. Cardiac output is the volume of blood pumped by the...
heart each minute and is determined by the force and frequency of ventricular contraction. Increased venous return increases ventricular (and therefore myocyte) stretch in diastole, resulting in increased filament overlap and hence, an increase in the number of available calcium-binding sites. This mechanism, which is the basis of Starling’s law of the heart, ensures ventricular output changes in response to changing venous return, thus, ensuring the output of the two ventricles is finely matched. The force of ventricular contraction is also affected by changes in contractility or the force of contraction for a given resting fibre length (Table 1). Inotropic agents prolong the action potential plateau duration, increasing $[\text{Ca}^{2+}]_i$, calcium release from the sarcoplasmic reticulum (SR) Ca$^{2+}$ uptake and lusitropy. Increased SR Ca$^{2+}$ content and L-type Ca$^{2+}$ channel activation increases myocardial Ca$^{2+}$ transients, resulting in greater contractile strength and inotropy. $\alpha_1$ adrenoceptors may also increase Ca$^{2+}$ levels in a manner similar to that in vascular smooth cells, but the increase is only 10–15% of that achievable by $\beta$ adrenoceptor mechanisms. $\alpha_2$ adrenoceptors have not been found on cardiomyocytes.

Vascular tone. Resistance vessel tone, sometimes termed afterload, will influence cardiac output both directly and through complex reflexes such as the baroreceptor reflex. For a given preload and contractility, the direct effect of a decrease

### Table 1

<table>
<thead>
<tr>
<th>Determinants of cardiac output</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocyte stretch</td>
</tr>
<tr>
<td>Changes in venous return</td>
</tr>
<tr>
<td>Changes in plasma volume</td>
</tr>
<tr>
<td>Contractility</td>
</tr>
<tr>
<td>Sympathetic tone</td>
</tr>
<tr>
<td>Circulating catecholamines</td>
</tr>
<tr>
<td>Exogenous inotropes</td>
</tr>
<tr>
<td>Heart rate</td>
</tr>
<tr>
<td>Sympathetic and parasympathetic tone</td>
</tr>
<tr>
<td>Circulating catecholamines</td>
</tr>
<tr>
<td>Exogenous drugs with chronotropic effects</td>
</tr>
</tbody>
</table>
in afterload is to increase cardiac output and vice versa as afterload rises. Importantly, during periods of haemodynamic shock, loss of a number of homeostatic mechanisms may impair contractility through acidosis, reductions in coronary flow and an adverse myocardial oxygen supply–demand ratio.

Microvascular flow. The microvasculature consists of regions of the circulation containing blood vessels of diameters less than 100 μm (den Uil et al., 2008). The homeostasis of these specialized areas is under myogenic, metabolic, immune and neural controls (Levick, 2003). Abnormalities of microvascular flow appear to play an important role in the pathophysiology of critical illness (De Backer et al., 2004; Ince, 2005; Spanos et al., 2010). Inotropic agents may influence this balance by altering both cardiac output and microvesSEL tone (De Backer et al., 2006; Jhanji et al., 2009b). Indirect effects of these drugs may also exert complex results on endothelial permeability and hence, blood volume, which is commonly reduced in critical illness (Adamson et al., 1998; Waschke et al., 2004).

Immune effects. Inotropic agents alter metabolic rate and the production of metabolically active molecules through perfusion-related, receptor and second messenger-mediated effects. These effects occur most frequently with adrenergic agonists and PDE inhibitors (PDEIs), which may increase total body oxygen consumption, peripheral insulin resistance, suppression of insulin secretion, increased fatty acid and lactate production and hyperglycaemia (Clutter et al., 1980; Galster et al., 1981). Importantly, hyperglycaemia may be associated with denudation of the endothelial glycocalyx and deleterious effects on the microcirculation (Lipowsky, 2005).

Metabolic effects. Inotropic agents have been shown to alter the state of activation of immune cells and may, therefore, have important effects on immune function, which are currently poorly understood (Oberbeck, 2006). Endothelial function is an important component of the capacity of the immune system to focus activity in specific tissue areas. Immune cell–endothelial interactions occur by shear-dependent or shear-independent mechanisms, both of which are influenced by inotropic agents. Shear-dependent mechanisms relate to flow through microvascular networks. At low flows, the probability of immune cells interacting with the endothelium increases (Lipowsky, 2005). Shear-independent mechanisms describe changes in the activation state of immune cells independent of flow. Activated cells have a greater chance of endothelial interaction at any given flow rate compared with quiescent cells.

**Pharmacology of endogenous vasoactive hormones**

**Catecholamines.** The endogenous catecholamines adrenaline, noradrenaline and dopamine are dihydroxybenzene (catechol) molecules. They act as neurotransmitters within the central and the sympathetic division of the autonomic nervous system and hormones in circulating blood. Catecholamines are synthesized in four stages within secreting nerve terminals and the adrenal enterochromaffin cells (Ganong, 2003). The first and rate-limiting step is the conversion of tyrosine to dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase. L-DOPA is decarboxylated to dopamine, which is taken up from the cytosol into neuronal vesicles in neurons and chromaffin granules in the adrenal medulla. Here, it is converted to noradrenaline (Philipu and Matthaei, 1988). In the adrenal medulla, noradrenaline re-enters the cytosol and is converted to adrenaline.

**Distribution and metabolism of endogenous catecholamines.** Only 10–20% of neuronally released noradrenaline reaches the circulation (Esler et al., 1990). The remainder is rapidly returned to the neurone by pre-synaptic uptake-1 or to perineuronal structures by uptake-2 transporters (Greafe and Bonisch, 1988). Reabsorbed noradrenaline is mostly recycled, but some is metabolized by MAO (Youdim et al., 1988). Sixty per cent of circulating adrenaline and noradrenaline remains free within the plasma. The remainder is bound covalently to either plasma proteins (11%) or to haemoglobin in erythrocytes (El-Bahr et al., 2006). There is a biphasic decay in plasma catecholamine levels, the first phase lasting around 5 min (uptake-2), and the second occurring over a month (plasma protein decay) (El-Bahr et al., 2006). Catecholamine metabolism occurs slowly in erythrocytes, which also act as a storage pool (Azouzi et al., 1996). Uptake-1 and 2 account for 25% of adrenaline clearance from plasma (Clutter et al., 1980). Circulating adrenaline and noradrenaline is subsequently metabolized, principally by COMT (Kopin, 1985). Clearance of catecholamines occurs principally in the liver and the lungs, and is increased by β-adrenoceptor-mediated mechanisms (Clutter et al., 1980). The kidneys excrete catecholamines almost entirely unchanged. There is also some peripheral uptake of catecholamines, most notably in vascular smooth muscle cells and the heart (Eisenhofer, 2001). The fate of peripherally released dopamine is similar to that of noradrenaline and adrenaline.

**Structure–activity relationships of catecholamines.** Structural differences in catecholamines result in some differences in receptor affinity and rates of metabolism. Substitution on the amino group of the catecholamine tail reduces α-receptor affinity but increases β-receptor affinity (Henkel et al., 1981; Lullman et al., 2000). Furthermore, β1 affinity is increased by the size of the substituent. The position of hydroxyl groups on the aromatic nucleus also alters adrenoceptor affinity as does hydroxyl substitution on the catecholamine tail. These latter groups are key in determining β2 affinity. For example, dopamine and dobutamine lack side chain β-OH groups and demonstrate low affinity and intrinsic activity at β2 adrenoceptors despite amino group substitutions (Mukherjee et al., 1976; Lullman et al., 2000). Metabolism by COMT is affected by the position of aromatic hydroxy groups. Resistance to MAO is conferred by substitution of methyl groups on the amino tail with larger groups or introducing small alkyl residues (Lullman et al., 2000). Alkylation of the primary amino group decreases affinity for uptake-1 (Greafe and Bonisch, 1988). Although catecholamine structure can determine the degree of adrenoceptor activation, agonists at specific adrenoceptor subtypes may still generate differing concentrations of second messengers such as cAMP, because of non-selective G-protein coupling (Xiao et al., 2003). Drug–receptor interactions are also influenced by polymorphisms of adrenoceptor genes (Nakada et al., 2010).
Function and distribution of adrenergic receptors. Adrenergic receptors are classified into \( \alpha \)-adrenoceptors and \( \beta \)-adrenoceptors and further into respective subtypes (Table 2) (Alexander et al., 2011). These GPCRs (Summers and McMartin, 1993; Alexander et al., 2011) are susceptible to down-regulation and desensitization (Bohm et al., 1997; Heck and Bylund, 1997), which is a particular problem in shock states such as sepsis (Tang et al., 1998). Although widespread throughout the body, only their cardiovascular distribution is discussed in this article. Adrenoceptor location within the CVS determines the pattern of response to circulating and neuronally released adrenergic agents (Brodde and Michel, 1999; Guimaraes and Moura, 2001) (Table 3). Adrenergic receptor expression is minimal in capillaries but increases with distance from the capillary in both arterioles and venules (Furness and Marshall, 1974). The responses to catecholamines, therefore, vary across vascular beds, for example, between mesenteric beds and skeletal muscle beds (Marshall, 1982). To date no \( \alpha_2 \) adrenoceptors have been found in the human myocardium, although other adrenoceptors are present there. Inotropy is provided predominantly by \( \beta \)-adrenergic mechanisms, although \( \alpha_1 \) adrenoceptors can bring about small increases in contractility.

Function and distribution of dopaminergic receptors. There are five subtypes of dopaminergic receptors (Alexander et al., 2011), classified in two groups: D1-like (subtypes DR1 and DR5) and D2-like (subtypes DR2, DR3 and DR4). Whereas dopamine

### Table 2

<table>
<thead>
<tr>
<th>Adrenoceptor</th>
<th>( \alpha_1 )</th>
<th>( \alpha_2 )</th>
<th>( \beta_1 )</th>
<th>( \beta_2 )</th>
<th>( \beta_3 )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subtypes</td>
<td>( \alpha_1 )</td>
<td>( \alpha_2 )</td>
<td>( \beta_1 )</td>
<td>( \beta_2 )</td>
<td>( \beta_3 )</td>
</tr>
<tr>
<td>Subclasses</td>
<td>( \alpha_1A, \alpha_1B, \alpha_1D )</td>
<td>( \alpha_2A, \alpha_2B, \alpha_2C )</td>
<td>( \beta_1 )</td>
<td>( \beta_2 )</td>
<td>( \beta_3 )</td>
</tr>
<tr>
<td>Principal ( G )-signalling protein</td>
<td>( G_{q/11} )</td>
<td>( G_{i/o} )</td>
<td>( G_\alpha )</td>
<td>AC/cAMP/PKA (stimulates)</td>
<td></td>
</tr>
<tr>
<td>Second messengers</td>
<td>PLC/DAG/IP_3/PKCC</td>
<td>AC/cAMP/PKA (inhibits)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Affinity for catecholamines</td>
<td>Ad = NAd</td>
<td>Ad &gt; NAd</td>
<td>Ad &lt; NAd</td>
<td>Ad &gt; NAd</td>
<td>Ad = NAd</td>
</tr>
<tr>
<td>Adrenoceptor subtype in myocardium and effect of agonism</td>
<td>( \alpha_1A )</td>
<td>None.</td>
<td>Pre-synaptic ( \alpha_2A )</td>
<td>( \beta_2 )</td>
<td>( \beta_1 )</td>
</tr>
<tr>
<td>Adrenoceptor subtype in vascular smooth muscle cells and effect of agonism</td>
<td>( \alpha_1A \rightarrow \alpha_2 )</td>
<td>Primarily ( \alpha_1A ) in arteries</td>
<td>( \alpha_2 )</td>
<td>( \beta_1 )</td>
<td>( \beta_1 )</td>
</tr>
<tr>
<td>Adrenoceptor subtype in vascular endothelium and effect of agonism</td>
<td>n/a</td>
<td>NO release vasorelaxation</td>
<td>( \beta_2 )</td>
<td>NO release vasorelaxation</td>
<td>(( \beta_1 ) role unknown)</td>
</tr>
</tbody>
</table>

AC, adenylate cyclase; Ad, Adrenaline; \( G_{i/o} \), \( G \)-protein \( \alpha \)-signalling subunit to which the relevant receptor is coupled; IP_3, inositol 1,4,5 trisphosphate; n/a, not applicable; NAd, Noradrenaline; \( \alpha_1 \rightarrow \alpha_2 \), implies \( \alpha_1 \) predominates over \( \alpha_2 \).

### Table 3

Adrenoceptor distribution determines vascular responses to catecholamines

<table>
<thead>
<tr>
<th>Vessel type</th>
<th>Arteries</th>
<th>Veins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-synaptic receptors close to synaptic junction</td>
<td>( \alpha_1 ) and ( \beta_1 )</td>
<td>( \alpha_1 ) and ( \beta_2 )</td>
</tr>
<tr>
<td>Extrajunctional post-synaptic receptors</td>
<td>( \alpha_2 ) and ( \beta_2 )</td>
<td>( \alpha_1 )</td>
</tr>
<tr>
<td>Coronary circulation</td>
<td>( \alpha_1 ) and ( \alpha_2 ) in large arteries only</td>
<td>( \beta_1 ) present in small and large arteries. ( \beta_1 \rightarrow \beta_2 )</td>
</tr>
<tr>
<td>Cerebral circulation</td>
<td>Poor sympathetic innervations</td>
<td>( \alpha )-adrenoceptor expression declines in smaller vessels</td>
</tr>
<tr>
<td>Splanchnic, Skeletal and Pulmonary</td>
<td>( \beta_2 \rightarrow \beta_1 )</td>
<td>( \alpha )-effects predominate over ( \beta ) in splanchnic circulation</td>
</tr>
<tr>
<td>Cutaneous circulation</td>
<td>( \alpha_2 )-adrenoceptors</td>
<td></td>
</tr>
</tbody>
</table>

Post-synaptic receptors close to the synaptic junction respond primarily to neuronal stimulation. Extrajunctional post-synaptic receptors respond primarily to hormonal stimulation or exogenous adrenergic agents. \( \beta_2 \rightarrow \beta_1 \) implies predominance of \( \beta_2 \) over \( \beta_1 \).
may activate both dopaminergic and adrenoceptors, the former are not activated by other endogenous catecholamines (Goldberg and Rajfer, 1985; Missale et al., 1998). All dopaminergic receptor subtypes have been identified in the kidney where they mediate natriuresis and diuresis (Bertorello and Aperia, 1990; Lokhandwala and Amenta, 1991). Cardiac dopaminergic receptors (DR, and DR<sub>3</sub>) mostly show some inotropic effect, although less pronounced than β-adrenoceptor-mediated responses (Motomura et al., 1978; Wang et al., 1991; Wakita, 2007). Dopamine receptors can also be identified in the adrenal medulla, autonomic ganglia, endothelium, and the renal, mesenteric and splenic vasculature, where they are both pre- (D<sub>1</sub>) and post-synaptic (D<sub>2</sub> & D<sub>3</sub>) (Missale et al., 1998). D<sub>1</sub> receptors are found in the media of blood vessels and cause vasodilatation. Vascular D<sub>2</sub> receptor activation can cause vasodilatation or constriction, depending on whether medial or adventitial (Zeng et al., 2007). The overall effect of non-selective dopaminergic activation, such as what occurs during low-dose dopamine infusion, is to reduce vascular tone.

Adrenaline. Adrenaline (also known as epinephrine) is a potent agonist at all adrenoceptors resulting in profound increases in cardiac output and heart rate, mean arterial pressure, and coronary blood flow. At low doses, passive stretch of pulmonary vessels accommodates increases in cardiac output, but as the plasma concentration of adrenaline increases, it will eventually increase pulmonary vascular resistance and hence, right ventricular afterload (Aviado and Schmidt, 1957). In addition to gross cardiovascular effects, myocardial oxygen demand rises because of increased heart rate and stroke work. Splanchnic oxygen consumption and hepatosplanchnic blood flow increase in association with an increased hepatic metabolic workload (Bearn et al., 1951). Metabolic effects include increased plasma glucose and lactate concentrations (Bearn et al., 1951; Clutter et al., 1980; Galster et al., 1981). The rise in lactate is of clinical importance as lactate is utilized in critical illness as a marker of tissue hypoperfusion. However, the increase in serum lactate induced by exogenous catecholamines does not appear to be associated with harm.

Noradrenaline. Noradrenaline (also known as norepinephrine) is an inotrope and a vasopressor (Levick, 2003). Noradrenaline is often incorrectly described as a pure vasopressor because of its α-adrenoceptor agonism and weak β<sub>2</sub>-adrenoceptor agonism (Alexander et al., 2011). However, noradrenaline has clearly described effects on contractility in critical illness (Jhanji et al., 2009b). The effects of noradrenaline on pulmonary vessels are similar to those of adrenaline (Aviado and Schmidt, 1957). Owing to the relative sparsity of cerebral vascular adrenoceptors, high doses of noradrenaline can be safely used to maintain cerebral perfusion pressure without significantly compromising flow in this circulation. Similarly the coronary circulation is protected to a certain extent from the vasoconstrictor effects of noradrenaline (Guimaraes and Moura, 2001). However, noradrenaline does decrease pulmonary, cutaneous, renal and splanchnic blood flow (Bearn et al., 1951; Hofbrand and Forsyth, 1973). Noradrenaline does not appear to cause an increase in serum lactate, possibly as this is a β<sub>2</sub>-mediated effect (Day et al., 1996). Compared with adrenaline, increases in plasma glucose are relatively modest and coincide with a neutral effect on splanchnic oxygen consumption in health (Bearn et al., 1951).

Dopamine. Dopamine acts on both dopaminergic and adrenoceptors, giving a complex cardiovascular response profile. At low doses (up to 5 μg·kg·min<sup>-1</sup>), primarily dopaminergic receptors are activated causing a decrease in vascular resistance and mild increase in cardiac output. At doses of 5–15 μg·kg·min<sup>-1</sup>, β-adrenoceptor effects lead to increases in cardiac output and heart rate (Sasada and Smith, 2003). Beyond this, α-adrenoceptor effects predominate, causing an increase in vascular resistance to the extent that cardiac output may decrease. At low doses, dopamine increases renal (Mousdale et al., 1988; Olsen et al., 1993) and splanchnic (Sato et al., 1987) blood flow. Dopamine causes a modest increase in metabolic rate, but without hyperlactataemia (Ensinger et al., 1993; 1995). Neurohumoral effects of dopaminergic activation in critical illness include a suppression of prolactin, thyroid and growth hormone secretion, whereas glucocorticoid synthesis is increased (Van den Berghe and de Zegher, 1996; Bailey and Burchett, 1997); these effects may explain important immune effects of dopamine in septic patients (Beck et al., 2004).

Other endogenous hormones

Vasopressin. In health, vasopressin is released from the posterior pituitary in response to osmotic, chemoreceptor and baroreceptor stimuli. In humans and most other mammals, one of the nine amino acids constituting vasopressin is arginine, although in some species, this is lysine. Vasopressin acts on vascular smooth muscle V<sub>1</sub> and oxytocin receptors (both G<sub>q</sub>/PLC coupled), causing vasoconstriction. Vasopressin may also activate vascular smooth muscle V<sub>2</sub> receptors (G<sub>s</sub>/adenylate cyclase/CAMP coupled) resulting in vasodilatation. Endothelial V<sub>1</sub>, V<sub>2</sub> and oxytocin receptor activation results in NO-dependent vasodilatation. The importance of vascular V<sub>2</sub> and oxytocin receptors is unsettled though. Overall, vasopressin stimulation tends to cause constriction, but the exact response depends on the precise location of receptor and the concentration of vasopressin in the vicinity. Vasopressin modulates autonomic function through activation of brainstem V<sub>1</sub> receptors and can modulate endocrine status as it stimulates adrenocorticotropic hormones release via V<sub>2</sub> receptors (Barrett et al., 2007). Exogenously administered arginine vasopressin (aVP) and lysine vasopressin differ. Tri-glycyl vasopressin, or terlipressin, is a prodrug slowly degraded by liver and kidney endo- and exopeptidases to lysine vasopressin, conferring a significantly longer duration of action after i.v. bolus than aVP. Terlipressin has a greater selectivity for vascular V<sub>2</sub> receptors but less selectivity for renal tubular V<sub>2</sub> receptors than aVP (Bernadich et al., 1998). Terlipressin may result in pulmonary vasoconstriction (Lange et al., 2007) and affect coagulation systems (Morelli et al., 2009) although aVP does not.

In septic shock, the administration of exogenous aVP (0.01–0.04 U·min<sup>-1</sup>) results in the reversal of vasodilatory shock. There are multiple mechanisms by which this may occur. Briefly, exogenously administered vasopressin may reverse a relative deficiency of the hormone seen in established sepsis. Vascular smooth muscle cation channel function and contractile machinery are affected such that vasorelaxation is
opposed. $V_1$- and $\alpha_1$-adrenoceptor crosstalk, an amelioration of autonomic dysfunction, an increase of other endogenous vasoconstrictors and a potential effect on both NO and glucocorticoid production may also contribute to the partial restoration of vascular reactivity to catecholamines and the reversal of vasodilatation (Barrett et al., 2007). The details of these mechanisms are beyond the scope of this article and may be found elsewhere (Barrett et al., 2007). Research into other compounds affecting vasopressin receptor systems in sepsis is currently ongoing (Rehberg et al., 2011).

**Exogenous inotropes and vasopressor agents**

**Dobutamine.** Dobutamine is a synthetic catecholine available as a racemic mixture (Majerus et al., 1989), with mixed $\beta_1$- and $\beta_2$-adrenoceptor effects, binding in a 3:1 ratio to $\beta_1$ and $\beta_2$-adrenoceptors respectively. It also demonstrates mild $\alpha_1$-adrenoceptor agonism (Ruffolo, 1987), which explains why decreases in vascular resistance do not persist at higher doses. Heart rate increases are modest and renal plasma flow is not greatly affected (Mousdale et al., 1988; Olsen et al., 1993). Dobutamine is widely used in the short-term treatment of severe heart failure and cardiogenic shock and is a first-line agent to increase cardiac output in septic shock, although usually in combination with a vasococonstrictor agent (Rudis et al., 1996; Beale et al., 2004). As dobutamine increases myocardial oxygen demand, it is used as a stressor in cardiac assessment (Patel et al., 2007).

**Dopexamine.** This synthetic structural analogue of dopamine has a greater potency at $\beta_1$-adrenoceptors but less potency at dopaminergic receptors. It was thought to be devoid of $\alpha_1$-adrenoceptor activity, but may, in fact, possess antagonist properties at this receptor (Martin and Broadley, 1995) and very weak agonism at $\beta_2$-adrenoceptors (Brown et al., 1985; Bass et al., 1987). Dopexamine's cardiovascular actions include chronotropy, inotropy and vasodilatation particularly in mesenteric, skeletal and renal beds (Mousdale et al., 1988; Olsen et al., 1993). These effects are believed to be due to a combination of direct $\beta_1$-adrenoceptor stimulation (vasodilatation and tachycardia), dopaminergic stimulation (decreasing renal and mesenteric vascular resistance) and an increased release of noradrenaline from sympathetic nerve terminals. However, these cardiovascular changes do not necessarily result in an increased myocardial oxygen demand (Dawson et al., 1985).

**Sympathomimetics**

**Phenylephrine.** Phenylephrine is a selective $\alpha_1$-adrenoceptor agonist predominantly causing proximal arterial effects (vasoconstriction) with terminal arteriolar sparing (Morelli et al., 2008). Phenylephrine reduces pulmonary vessel calibre because of a combination of pulmonary vasoconstriction and also passively if a drop in cardiac output occurs (Aviado and Schmidt, 1957). A reflex bradycardia can often be seen with administration whether cardiac output is affected or not. Potent and selective $\alpha_1$-adrenoceptor agonists decrease renal and splanchnic blood flow (Hoffbrand and Forsyth, 1973), which may give cause for concern when used to increase arterial pressure in critically ill patients.

**Metaraminol.** Metaraminol is a mixed direct- and indirect-acting sympathomimetic (Foster, 1966). It has direct action at $\alpha_1$-adrenoceptors and increases the amount of noradrenaline in the synaptic cleft through displacement from pre-synaptic storage vesicles and by competing with noradrenaline for uptake-1, thus, leading to $\alpha_2$-adrenoceptor and $\beta_1$-adrenoceptor agonism. A relatively long half-life is conferred by a resistance to MAO and COMT. Although this drug has $\beta_2$-adrenoceptor agonist actions, vasoconstriction causes a reflex bradycardia and may result in an overall fall in cardiac output (Dart, 2004). Pulmonary artery pressures can increase because of vasoconstriction although with variable changes in pulmonary flows due to the mixed effects on cardiac output (Aviado and Schmidt, 1957). It is mainly used during surgery or critical illness to reverse short-term episodes of hypotension.

**Ephedrine.** Ephedrine is a mixed direct- and indirect-acting sympathomimetic. It is taken up (U1) into nerve terminals and displaces noradrenaline from vesicles and nerve terminals to cause $\alpha_2$-adrenoceptor effects. The problem of tachyphylaxis can occur with prolonged use of the drug because of depletion of noradrenaline (Moss and Renz, 2000). Ephedrine also exhibits mild direct $\beta_2$-adrenoceptor activity (Kobayashi et al., 2003) with increases in cardiac output of up to 20% due to increases in heart rate and stroke volume (Cohn, 1965). Myocardial oxygen consumption is increased in common with all catecholamines and sympathomimetics. Other effects include bronchodilation, respiratory stimulation, mydriasis and tocolysis (Sasada and Smith, 2003). Studies in dogs suggest a decrease in pulmonary vascular resistance with an associated increase in pulmonary blood flow (Aviado and Schmidt, 1957). MAO and COMT resistance confers a longer half-life, and the drug is mainly excreted unchanged in the urine (Sasada, 2003).

**PDEI**

PDE has 11 isoforms, the important isoform for inotropic effects being PDE III. Methylxanthines (theophylline, caffeine) are non-selective PDEs whereas amrinone, milrinone (bipyrindines) and enoximone (imidazolone) are PDE III selective. These drugs enhance cAMP and PKA levels through non-receptor-dependent mechanisms and increase inotropy, chronotropy and lusitropy while decreasing preload and afterload (Figures 1 and 2). These agents are potent pulmonary vascular dilators and are considered particularly useful in the treatment of acute severe right heart failure and pulmonary hypertension (Greeley et al., 2000).

**Amrinone and milrinone.** Amrinone and milrinone are bipyrindine derivatives. Milrinone is more commonly used than amrinone because of the latter's tendency to cause dose-dependent thrombocytopenia. This has been associated with the metabolite N-acetyl-amrinone (Lehtonen et al., 2004). Milrinone is a more potent analogue of amrinone (Alousi and Johnson, 1986), which is mainly excreted unchanged in the urine. In common with all PDE III inhibitors, milrinone has a similar cardiovascular profile to dobutamine. However, milrinone increases heart rate to a lesser extent despite a greater tendency to decrease systemic vascular resistance. Milrinone decreases pulmonary vascular resistance and pulmonary artery pressure with a smaller effect on myocardial oxygen demand (Prielipp et al., 1996; Petersen and Felker, 2008). This may be due to compensation by
preload and afterload reductions, leading to decreased ventricular wall stress (Colucci, 1991). Left ventricular pressure–volume loops suggest that lusitropy is enhanced and right ventricular afterload is decreased (Colucci, 1991). There has been some suggestion that milrinone does not, in fact, increase contractility to any significant degree, the vasodilator actions being more significant, although this is controversial (Ludmer et al., 1986; Royse et al., 2007).

**Enoximone.** Enoximone is an imidazolone and a selective PDE III inhibitor. In vivo comparisons demonstrate less inotropy and chronotropy, but more lusitropy when compared with milrinone. However, at clinical doses, only milrinone produced significant inotropic and lusitropic effects (Zausig et al., 2006). Enoximone may increase fat metabolism in comparison with glucose, which could be beneficial in septic shock (Trager et al., 2001). Enoximone is metabolized by saturable enzyme systems and the active metabolites are renally excreted, although the parent compound itself is not (Lehtonen et al., 2004). The half-lives of PDE III inhibitors increase in renal failure, which is common among critically ill patients.

**Aminophylline.** Aminophylline is the ethylenediamine salt of theophylline and was commonly used in the treatment of severe acute bronchial asthma and also as a treatment for increasing urine output in impending acute kidney injury. Aminophylline also has mild inotropic activity and continues to be used, albeit infrequently, for this purpose.

**Levosimendan**

Levosimendan is a myofilament calcium sensitizer and a novel inotrope that increases contractility without increasing cAMP levels appreciably at clinically recommended doses. Unlike other inotropes, levosimendan does not exert its action through potentially harmful increases in intracellular Ca\(^{2+}\). This may explain why this agent does not impair diastolic relaxation and cardiac rhythm, and has less harmful effects on myocardial energetics (Toller and Stranz, 2006; Tavares et al., 2008). Levosimendan binds to the N-terminal of troponin C with high affinity, but at [Ca\(^{2+}\)]i levels, which are only reached in systole, prolonging the interaction of myosin and actin filaments through inhibition of troponin I. This contrasts with other filament sensitizers that remain bound at Ca\(^{2+}\) concentrations, which occur in diastole, thus, impairing diastolic relaxation and ventricular compliance (Toller and Stranz, 2006; Tavares et al., 2008). Levosimendan has PDE III inhibitory actions, but these are not thought to be clinically significant (Toller and Stranz, 2006). Importantly, the levosimendan metabolite OR-1896 has similar calcium-sensitizing actions to the parent molecule, maintaining the inotropic effect of levosimendan once an infusion is stopped (Toller and Stranz, 2006). The cardiovascular effects of levosimendan include...

---

**Figure 2**

Intracellular mechanisms of catecholamine and PDEI modulation of vascular tone. Catecholamines and PDEIs modulate [Ca\(^{2+}\)]i and, therefore, vascular smooth muscle cell tone as Ca\(^{2+}\) activates myosin light chain kinase (MLCK) and downstream contractile events. Vasoconstriction follows cAMP decreases or PLC stimulation. Vasodilatation follows cAMP increases. cAMP is broken down by PDE and generated by adenylate cyclase (AC). β adrenoceptors positively couple to AC by Gs whereas α2 adrenoceptors negatively couple via Gi. cAMP activates PKA, which is responsible for enhancing calcium pumping into sarcoplasmic reticulum (SR) and extracellular spaces, for MLCK inhibition and cellular hyperpolarization consequently inhibiting voltage-sensitive calcium channel (VSCC). α1 adrenoceptors positively couple to PLC via Gq resulting in the generation of inositol 1,4,5 trisphosphate (IP3) and DAG from phosphatidylinositol 4,5 bisphosphate (PIP2). IP3 activates SR calcium channels, increasing [Ca\(^{2+}\)]i while DAG and calcium both stimulate PKC. PKC enhances contractile element sensitivity. Receptor-operated calcium channels (ROCC) are positively coupled to α1 adrenoceptors via non Gq subunits. NO is generated by NOS 3 in endothelium following α2 and β adrenoceptor ligation. NO diffuses to vascular smooth muscle resulting in protein kinase G mediated decreases in calcium, PDE inhibition and vasodilatation. The endothelium is thus a powerful modulator of vascular tone. S’AMP, S’ adenosine monophosphate; Gs/i/q, relevant G-protein α subunit.
increased heart rate when high-dose loading and infusions are used, possibly via baroreceptor-mediated pathways. In vascular tissue, levosimendan acts as a vasodilator by decreasing the sensitivity of myofilaments to Ca²⁺ and activating of K⁺ channels. This results in hyperpolarization, decreased Ca²⁺ entry and vasodilatation (Toller and Stranz, 2006; Petersen and Felker, 2008). Levosimendan is generally used for 24 h due to OR-1896 accumulation, which has a terminal half-life of 96 h (Toller and Stranz, 2006).

Changes to pharmacokinetics and pharmacodynamics of inotropic agents during critical illness

Alterations in receptor and intracellular signalling pathways.

Agnost binding to adrenoceptors causes coupling with G proteins (Figures 1 and 2). These G proteins consist of three subunits (α, β, and γ), the type of α subunit denoting the type of G-protein (Gs is Gαs, Gq is Gαq, G12 is Gα12). On coupling, βγ subunits exchange GDP for GTP, dissociate from the complex and are active until the GTP is hydrolysed back to GDP. α-GDP then reassociates with the βγ subunit complex and is available to couple with another adrenoceptor. The duration of signalling is inversely related to the speed with which α-GTP is hydrolysed to α-GDP, a process promoted by regulator of G-protein signalling (RGS) molecules (Hendriks-Balk et al., 2008). RGS mRNA is increased by endotoxin and may, therefore, constitute one mechanism of diminished adrenoceptor agonist responses in sepsis (Panetta et al., 1999; Hendriks-Balk et al., 2009; Riekenberg et al., 2009). β-adrenoceptors couple predominantly to G-stimulatory (Gs) proteins but also couple to G-inhibitory (Gi) proteins (Bohm et al., 1995; Martin et al., 2004). Prolonged β2 adrenoceptor agonism induces both reductions in Gi and increases in Gs. This switch to Gi signalling has been confirmed in human and animal sepsis studies (Bohm et al., 1995; Bernardin et al., 1998; Wu et al., 1999, 2003). Evidence also exists of a predominant down-regulation of most adenylate cyclase isoforms in several tissues in response to endotoxaemia, potentially further affecting adrenoceptor signalling processes (Risse et al., 2007).

Sustained adrenoceptor agonism frequently occurs in sepsis and may result in desensitization and down-regulation of α and β adrenoceptors (Bleck and Bylund, 1997). This occurs partly through the above mechanisms and also by activation of PKA and PKC, which phosphorylate GPCRs indiscriminately. Agonist-bound adrenoceptors are also specifically phosphorylated by G-protein receptor kinases (GRKs). Both mechanisms result in receptor internalization, although GRK phosphorylation of activated receptors also results in further uncoupling from Gαs signalling subunits through the attachment of β-arrestin molecules. GRK 2 (phosphorylates β2 adrenoceptors) may be up-regulated in sepsis (Kadoi et al., 2002). In addition to these effects on existing adrenoceptors and their signalling partners, sustained adrenoceptor agonism also reduces generation of new adrenoceptors. As a result, adrenoceptors become refractory to agonism, signal for shorter periods and in atypical ways. These changes occur in heart failure but are more pronounced in the heart in sepsis because of synergistic effects of endotoxin and TNF-α. Sepsis also up-regulates other related pathways such as PDE III (Choi et al., 2009).

Free radicals and the auto-oxidation of catecholamines.

Sepsis is associated with the generation of NO and subsequently peroxynitrite, which deactivates catecholamines (Takakura et al., 2003) and disturbs adrenoceptor function (Takakura et al., 2002; Lewis et al., 2005). Catecholamines are also degraded by superoxide to quinones. This is autocatalytic as superoxide is regenerated. This reaction may be more important in shock states when pH decreases and free radical and catecholamine levels are elevated. Quinones are neurotoxic (Smythies and Galzigna, 1998) and cardiotoxic (Yates et al., 1981; Bindolli et al., 1992; Neri et al., 2007). The inverse relationship between plasma levels of adrenochromes and catecholamines suggests refractoriness to catecholamine therapy in shock states may relate to this deactivation (Macarthur et al., 2000), in particular by polymorphonuclear leucocytes (Matthews et al., 1985).

Additional effects of inotropes and vasopressors in critical illness

Regional blood flow.

Reductions in renal and hepatosplanchnic blood flow are a concern in critical illness. However, there is no evidence that this occurs in resuscitated states of pathological vasodilatation treated with noradrenaline (Reinelt et al., 1997), and there may be some improvement in microvascular flow and tissue oxygenation (Risoe et al., 2004; Jhanji et al., 2009b). Dopamine, noradrenaline and adrenaline produce similar splanchnic blood flow in moderate septic shock, although in severe septic shock, adrenaline decreases splanchnic blood flow when compared with noradrenaline (De Backer et al., 2003). Phenylephrine also reduces splanchnic blood flow when compared with noradrenaline in septic shock (Reinelt et al., 1999). Although doxepamine may improve tissue oxygenation and microvascular flow (Jhanji et al., 2010), the evidence for this in the hepatosplanchnic bed is equivocal and may only occur in some patient groups (Renton and Snowden, 2005). Vasopressin analogues also decrease hepatosplanchnic blood flow, but have unique effects on intrarenal haemodynamics in shock (Albert et al., 2004).

Metabolic changes.

α adrenoceptors inhibit the pancreatic release of insulin whereas β adrenoceptors stimulate glucagon release, and hepatic glycogenolysis and gluconeogenesis. This increases serum glucose concentration. Catecholamines also stimulate lipolysis, increasing plasma free fatty acids. These effects are particularly pronounced with adrenaline (Ensinger et al., 1995) and relate to the intrinsic ability of the catecholamines to generate cAMP (Barth et al., 2007). The effect on protein catabolism is complex as β1 agonism can inhibit proteolysis (Navegantes et al., 2001) but hypermetabolic states with protein breakdown result when catecholamine levels remain elevated. Dopamine suppresses growth hormone and thyroid-stimulating hormone release, potentially exacerbating protein losses (Schilling et al., 2004). β2 adrenoceptor-mediated increases in lactate relate to increased Na⁺/K⁺ ATPase activity, increasing VO₂ (Levy et al., 2008). VO₂ also increases through β adrenoceptor-mediated increases in substrate flux and mitochondrial uncoupling. Unlike in health (Bearn et al., 1951), in the hepatosplanchnic bed in sepsis, splanchnic VO₂ may not necessarily relate directly to hepatic metabolic workload though (Reinelt et al., 1997; 1999). Although catecholamines directly cause mitochondrial
complex inhibition, mitochondrial respiratory efficiency during endotoxaemia may improve in some tissues (Porta et al., 2006; 2009; Regueira et al., 2008). Studies suggest that adrenaline, noradrenaline and dobutamine may be better in this regard than dopamine (Jakob et al., 2002; De Backer et al., 2003; Guerin et al., 2005). Mitochondrial uncoupling protein (UCP) 2 expression is up-regulated in the heart in sepsis (Roshon et al., 2003), possibly as a means to decrease free radical production (Boss et al., 2000). However, this decreases mitochondrial Ca\(^{2+}\) uptake and permits a greater degree of arrhythmogenic Ca\(^{2+}\) sparking in addition to impairing excitation–contraction efficiency (Turner et al., 2011). It is important to note that arrhythmias occur more frequently in association with dopamine treatment for septic shock (De Backer et al., 2010) and that quinone-induced mitochondrial UCP and transition pore opening may be a mechanism of cytotoxicity (Berman and Hastings, 1999).

**Bacterial growth.** Iron is required for several intracellular processes essential for the growth of bacteria. Some strains of bacteria sequester iron by secreting siderophores that bind iron and reuptaking the siderophore–iron complexes. Catecholamines, particularly noradrenaline, can increase bacterial iron uptake, stimulating growth (Coulanges et al., 1997). There is also some evidence that catecholamines act as host signals to enhance virulence factors and gene transfer in commensal organisms such as *Escheria coli* (Hughes and Sperandio, 2008; Peterson et al., 2011).

**Immune system.** Adrenoceptors can be identified in all immune cells as well as in the endothelium and play a central role in many aspects of the immune response, which is clearly of particular importance during critical illness. Acutely, adrenaline infusion results in a β-adrenoceptor-mediated leukocytosis, predominantly cytotoxic cells, from the marginating pool (Rogausch et al., 1999; Dimitrov et al., 2010). However, the initial leukocytosis seen in endotoxaemia is α\(_2\) adrenoceptor mediated (Altenburg et al., 1997). Various catecholamines have been shown to either increase (Horn et al., 2005) or decrease neutrophil–endothelial (Boxer et al., 1980; Schmidt et al., 1998) and lymphocyte–endothelial interactions (Carlson et al., 1996). Different catecholamines modulate the expression of integrins on the surface of leukocytes (Trabold et al., 2007), decrease chemotaxis (Silvestri et al., 1999) and phagocytosis (Gosain et al., 2007), decrease neutrophil α-defensin secretion (Riepl et al., 2010), and decrease respiratory burst in neutrophils (Weiss et al., 1996; Lunemann et al., 2001). There are also effects on lymphocyte proliferation and differentiation such that CD8\(^+\) cells are decreased and antibody secretion by B-cells is decreased (Bergquist et al., 1994; Qiu et al., 2005). α\(_1\) and β\(_2\) adrenoceptor mechanisms increase apoptosis in lymphocytes (Jiang et al., 2009), although dopamine-induced prolatin suppression may also play a role (Zhu et al., 1997). Catecholamines have complex effects on cytokine release, partly dependent on the stage of sepsis (Bergmann et al., 1999). In general, pro-inflammatory cytokine release is reduced by β\(_2\) adrenoceptor agonism, while anti-inflammatory cytokines such as IL-10 increase (Szabo et al., 1997; Muthu et al., 2005). α-adrenoceptor agonism results in opposite effects. α\(_2\) adrenoceptors control neutrophil homing in endotoxaemia (Abraham et al., 1999), and G\(_i\) signalling is important in leucocyte extravasation (Pero et al., 2007), but the situation may differ in haemorrhage (Arcaroli et al., 2002). In general, dopamine and adrenaline appear to have immunosuppressive actions while noradrenaline is less so, probably because of a weaker effect at β\(_2\) adrenoceptors. Endogenous and exogenous catecholamines may contribute to late-phase immunosuppression commonly seen after major surgery, trauma or sepsis. Alternative agents such as vasopressin also have immune effects (Hofstetter et al., 2007; Russell and Walley, 2010).

**Apoptosis, inflammation and other receptor systems.** Other than apoptosis in lymphocytes (Jiang et al., 2009), several catecholamines and PDEs induce heart, vascular smooth muscle and skeletal muscle myocyte apoptosis (Burnistin et al., 2005; Garcia-Cazarin et al., 2008). Quinone molecules have been shown to open the mitochondrial permeability transition pore (Berman and Hastings, 1999), an important step in inducing cell death pathways. Inflammatory pathways under catecholamine modulation are those centred on NF-kB activation; these are responsible for cytokine gene regulation (Arcaroli et al., 2002). Enzymes involved in cell survival, such as glycogen synthase kinase 3B (Ballou et al., 2001), PI-3-kinase (Yambolieva and Mutafova-Yambolieva, 2005) and ERK (Wright et al., 2008) have also been shown to be activated by α\(_i\) and α\(_j\) agonism, often through actions of G\(_\alpha\) subunits. Proteosomal inhibition and concomitant up-regulation of heat shock proteins have also been demonstrated (Costa et al., 2009). Although this is deemed beneficial in ischaemia reperfusion, persistent adrenergic agonism is likely to increase apoptotic and anti-inflammatory responses. This may contribute to the cardiac dysfunction (Moretti et al., 2002; Chopra and Sharma, 2009), immune anergy and organ dysfunction seen with sepsis. Transactivation of endothelial growth factor receptor (EGFR) by α adrenoceptor agonism has been shown to be important in vascular contractile responses (Hao et al., 2006), but the significance of this signalling in the context of critical illness is not known.

**Coagulation & platelets.** Both α and β adrenorsceptors mediate the eoxymosis of von Willebrand factor (vWF), clotting factor VIII, tissue plasminogen activator and chemoattractant IL-8 from Weibel–Palade bodies in endothelial cells. However, PKA results in partial stabilization of these bodies while G\(_i\) signalling does not (Rondaj et al., 2006). The activation of G\(_i\) by platelet α\(_i\) adrenoceptors is necessary to decrease a tonic inhibition on platelet aggregation (Maayani et al., 2001). The aggregation of platelets is enhanced only in the presence of very high levels of circulating catecholamines (Ikarugi et al., 2003) such as in sepsis, as β-adrenoceptor stimulation probably mitigates that of α stimulation at lower plasma catecholamine levels (Yu and Latour, 1977). Platelet activation may impede microvascular flow and tissue oxygen delivery by a combination of enhanced platelet–leucocyte–endothelial interactions (von Hundelshausen et al., 2009) and microthrombus formation. Although epinephrine can increase factor VIII and platelet aggregation, the severity of sepsis is actually associated with diminished platelet aggregation (Yaguchi et al., 2004), and epinephrine has been shown to decrease coagulation in endotoxaemia (van der Poll et al., 1997).
Gastrointestinal tract. The gut is richly innervated and is, therefore, responsive to neuronally released and circulating catecholamines (De Ponti et al., 1996). In critical illness the use of catecholamines and degree of motility disturbance are associated (van der Spoel et al., 2006), although the severity of illness and use of sedative drugs disturbs motility and also associates with catecholamine use. Endogenous catecholamines have all been shown to directly inhibit motility in the colon, ileum and upper gastrointestinal tract in vitro (Beani et al., 1969; Kosterlitz et al., 1970) and in vivo (Dive et al., 2000). In vitro studies suggest this may be less of an issue with some synthetic catecholamines (Fruhwald et al., 2000).

Clinical trials of inotropes and vasopressor agents

Sepsis. Septic shock is a common presentation in the critical care unit, resulting in impaired ventricular function, pathological vasodilatation, hypovolaemia, deranged microvascular flow and increased capillary permeability (Dellinger, 2003). Inotropic and vasopressor agents are, therefore, among the most important therapies in the treatment of this syndrome. However, despite the fundamental importance of appropriate vasoactive drug use in the treatment of patients with septic shock, the clinical evidence base is surprisingly limited. In combination with i.v. fluids, the objective of vasoactive drug therapy is to restore cardiac output, arterial pressure, and hence, tissue perfusion and oxygenation. Once adequately fluid-resuscitated a combination of vasopressor and/or inotropic agents may be used to achieve the desired physiological targets. There is an extensive debate regarding the most appropriate physiological goals for vasoactive drug therapy in septic shock, as well as in other patient groups. It is beyond the scope of this review to explore this issue in detail. However the most important goals that continue to be debated are mean arterial pressure, cardiac output, systemic oxygen delivery (DO2) and, more recently, mixed/central venous saturation (SvO2). However, there is also a growing body of evidence that vasoactive drug therapies exert many important effects within the microcirculation, which may not be immediately identified from changes in global haemodynamics (De Backer et al., 2006; Jhanji et al., 2009a; 2010). There is no standard dosing regimen for inotropic agents; there is considerable variability in practice, although the search into dose selection is likely to prove of even greater value than research comparing different agents. However, it seems likely that the optimal approach will involve the use of inotropic agents in the lowest effective dose and for the minimum period of time. There has been some confusion between the effects of treatments used to achieve haemodynamic goals and the monitoring device used to provide the data. In particular there has been some concern regarding excess mortality related to use of the pulmonary artery catheter. However, three large multi-centre trials have now confirmed the safety of this device (Richard et al., 2003; Sandham et al., 2003; Harvey et al., 2006).

The majority of vasoactive agents in current use are catecholamine based. Adrenaline, noradrenaline and dobutamine are probably the most commonly used agents. A number of clinical trials have explored the use of specific haemodynamic goals such as cardiac index, DO2 and SvO2 (Hayes et al., 1994; Gattinoni et al., 1995; Rivers et al., 2001). The use of such goals may be effective in the early stages of resuscitation of patients with septic shock (Rivers et al., 2001). However, later application for prolonged periods or the aggressive pursuit of goals in patients who do not respond has proved ineffective (Gattinoni et al., 1995; Alia et al., 1999) and may even be harmful (Hayes et al., 1994). Use of high-dose catecholamine therapy to achieve purely physiological therapeutic goals may contribute to excess mortality (Rona, 1985). In recent years, the use of adrenaline has declined in favour of dobutamine because the potential vasodilator effects of the latter agent are thought to improve tissue microvascular flow. However, in a multi-centre trial, the use of a combined regimen of dobutamine and noradrenaline was associated with similar clinical outcomes to adrenaline alone (Annane et al., 2007). In another trial, adrenaline was compared directly with noradrenaline, again with similar mortality rates (Myburgh et al., 2008). Interestingly more patients in the adrenaline group were withdrawn primarily because of transient metabolic effects of this drug (Myburgh et al., 2008). PDEIs are also an option in the treatment of septic shock. Like dobutamine, the vasodilator properties of this group of agents are believed to enhance tissue microvascular flow, although this has not been clearly demonstrated in studies in human sepsis. However, the consequent reduction in arterial pressure may necessitate an increased dose of vasopressor agent and the longer half-life, which is further increased in renal failure (Lehtonen et al., 2004), can limit the flexibility of this treatment approach.

In terms of vasopressor therapy, the findings of a recent large multi-centre trial comparing dopamine with noradrenaline in a mixed population of critically ill patients suggest noradrenaline use is associated with better clinical outcomes (De Backer et al., 2010). It is likely that these findings, in fact, relate to harmful chronotropic effects of dopamine resulting in tachycardia and perhaps myocardial ischaemia (De Backer et al., 2010). The role of dopamine in the prevention and treatment of acute kidney injury is discussed below. There is continued interest in the use of vasopressin in septic shock as this agent may have a particular role in the treatment of catecholamine-resistant loss of vascular tone. Both terlipressin and aVP have been used in this context, although the latter has been more thoroughly studied in humans. Findings of a large trial suggested no difference in clinical outcomes between noradrenaline and a combined regimen of aVP and noradrenaline (Russell et al., 2008). However, there is some concern that the pure vasopressor analogues of vasopressin may result in further impairment of microvascular flow, particularly in the hepatosplanchnic bed (Martikainen et al., 2003; Westphal et al., 2004). Vasopressin is likely to be of value in the case of hypotension due to vasodilatation but may not necessarily be beneficial where this is due to low cardiac output as the combination of coronary vasoconstriction and increased ventricular afterload may result in further compromise of myocardial function (Muller et al., 2008; Simon et al., 2009). Furthermore, vasopressin analogues (particularly terlipresin), have a longer half-life than the catecholamines and cannot be titrated to effect as easily. Further research directly comparing the effects of vasopressin and noradrenaline may provide more useful guidance on the use of these agents (Russell et al., 2008; Gordon et al., 2010).
In one very small randomized trial, there were no differences in physiological parameters in patients treated with phenylephrine compared with noradrenaline in septic shock (Morelli et al., 2008). However it is questionable whether the effects of pure α-agonism are always beneficial in septic shock, again due to concerns regarding the effect of pure vasoconstrictor agents on microvascular flow. There is some limited data to suggest that metaraminol could be used as a vasopressor agent in septic shock (Natalini et al., 2005). Because this agent may be administered via a peripheral vein as well as a central venous catheter, it has some application as a vasopressor in the early period of stabilization when a patient with haemodynamic shock is first identified but has yet to have a central venous catheter inserted.

There may be important interactions between inotropic drugs and patient genotype (Nakada et al., 2010). The CysGlyGln haplotype of the β2 adrenoceptor gene is associated with altered responses to adrenergic agonists in asthmatic patients. Recent research has suggested that certain polymorphisms of this adrenoceptor gene may be associated with greater inotrope requirements and increased mortality from septic shock. Further understanding of the pharmacogenomics of inotropic agents may allow more appropriate drug therapy for individual patients. However, there is very little research data in this area at present.

Acute kidney injury. There has been some interest in the use of inotropic agents, particularly dopaminergic agents, in the prophylaxis and treatment of acute kidney injury. For many years, the renovascular effects of low-dose dopamine were believed to be beneficial in both respects. Certainly in the 0–5 μg-kg-min⁻¹ dose range, dopamine promotes diuresis and natriuresis, but there has been little evidence that this effect ameliorates any harmful effects on global renal function. The findings of a randomized trial confirm that the physiological effects of this agent in terms of renal function are not associated with any improvement in the need for haemodialysis or other relevant clinical outcomes (Bellomo et al., 2000). Since the publication of these findings, most critical care physicians have stopped using dopamine for this indication (Kellum and Decker, 2001). Although not an inotrope but, in fact, an antihypertensive agent, the selective D1 agonist and dopamine analogue fenoldopam has also been studied for the prevention of acute renal failure in various settings. While still requiring a definitive trial to prove the case, there is current evidence suggesting fenoldopam may ameliorate acute kidney injury, although not from contrast-induced causes (Halpenny et al., 2002; Stone et al., 2003; Bove et al., 2005; Morelli et al., 2005; Tumlin et al., 2005; Landoni et al., 2007; 2008). Contrast-induced nephropathy occurs in 11% of critically ill patients and is defined as an absolute (0.5 mg·DL⁻¹) or relative increase (>25%) in serum creatinine over 48–72 h following the use of nephrotoxic radio-opaque contrast agents in diagnostic imaging procedures (Mehran and Nikolsky, 2006; Rashid et al., 2009). There has also been some interest in the effect of dopexamine on perioperative acute kidney injury. However, these small studies have not clearly confirmed or refuted such an effect of dopexamine infusion (Schmoelz et al., 2006; Jhanji et al., 2010).

Severe heart failure and cardiogenic shock. Of all categories of patients who require inotropic therapy, those with severe heart failure are the most challenging to treat. In most cases, inotropes can only be regarded as a bridging therapy to stabilize patients while definitive, often surgical, interventions can be arranged. Few agents have been associated with improved outcomes in clinical trials and several with reduced survival. This creates a dilemma for the clinician faced with a patient with severe haemodynamic shock who is unlikely to survive without some form of restoration of homeostasis through improved cardiac output and arterial pressure. It would not be considered ethical to randomize such patients into the placebo arm of a clinical trial that does not provide some form of vasoactive drug therapy. Thus, it seems likely that vasopressor and inotropic therapies do prolong survival, however, briefly.

Findings of a recent large multi-centre trial discussed above suggest that vasopressor therapy with dopamine may be associated with an increased mortality when compared with noradrenaline. This effect was most obvious in the subgroup of patients with heart failure in whom the significant chronotropic effects of dopamine are most likely to cause harm due to myocardial ischaemia (De Backer et al., 2010). It seems likely that the use of dopamine will decline following this trial. Unfortunately, the findings of other trials have provided little in the way of clear guidance for clinical practice.

Neither dobutamine nor milrinone has proved to be superior to the other in the treatment of heart failure (Petersen and Felker, 2008). Furthermore milrinone treatment is associated with an increased mortality over baseline in heart failure patients (Packer et al., 1991). Reasons for this are unclear, but PDE III inhibition causes increased plasma renin levels through non-renal baroreceptor-, CAMP-mediated mechanisms in juxtaglomerular cells (Chiu and Reid, 1996; Chiu et al., 1999).

There has been great interest in the use of the novel agent levosimendan in patients with severe heart failure and cardiogenic shock. Early data have suggested that treatment with levosimendan in these circumstances may improve cardiac performance with little or no increase in myocardial work. Initial small clinical trials supported this theory with evidence of improved haemodynamics and, perhaps, survival after a 24 h infusion. However, larger trials failed to confirm this survival benefit when compared with dobutamine therapy in patients with heart failure (Mebazaa et al., 2007). When compared with placebo, levosimendan use was associated with increased mortality at 90 days, and a higher incidence of hypotension and arrhythmia (Petersen and Felker, 2008). However, given the problematic evidence base for inotropic therapy in heart failure, there is still an argument for the use of levosimendan, in particular, after cardiac surgery (Braun et al., 2006) and in patients with right heart failure where pulmonary vasodilator effects may be important.

Major surgery. Anaesthetists commonly use various mild inotropic or vasopressor agents in bolus doses to correct the cardiovascular effects of general and regional anaesthesia. Ephedrine, phenylephrine and metaraminol have proved popular for this indication. A small proportion of patients who undergo major surgery will develop haemodynamic shock and require an inotrope or vasopressor infusion. Such cases are generally managed in a similar way to that described for
patients with septic shock. However, there has also been a long-standing interest in the use of inotropic agents as part of a ‘goal-directed’ approach to haemodynamic therapy with pre-determined goals, including cardiac index, systemic oxygen delivery and/or venous saturation. In fact, most clinical trials of inotropic agents in patients undergoing major surgery have related to this approach, which may improve outcome by augmenting oxygen delivery to the tissues (Jhanji et al., 2010). Once again, although a number of clinical trials of goal-directed perioperative haemodynamic therapy have been performed, most have been small single-centre trials. The findings of these trials have proved inconsistent because of important methodological variations including differences in patient group, timing and duration of interventions, treatment end-points, therapies used to achieve end points, and choice of monitoring technology. Some trials identified reductions in morbidity (Berlauk et al., 1991; Polonen et al., 2000; Pearse et al., 2005) and mortality (Boyd et al., 1993; Wilson et al., 1999; Lobo et al., 2000). Others, however, failed to show any benefit (Ueno et al., 1998) particularly in the case of vascular surgery (Bender et al., 1997; Ziegler et al., 1997; Valentine et al., 1998; Bonazzi et al., 2002).

Dopexamine has been the most frequently investigated agent in the surgical population. This agent may have specific beneficial effects on tissue microvascular flow and oxygenation in patients following major gastrointestinal surgery (Jhanji et al., 2010). Interestingly, the findings of a metagression analysis suggest that dopexamine may, in fact, have a biphasic effect on outcome, with improved survival in low doses (<1 μg·kg⁻¹·min⁻¹) but reduced survival at higher doses (Pearse et al., 2008). The β₂-agonist effects of dopexamine often result in significant tachycardia at higher doses, and, in common with dopamine, it seems likely that this may be associated with an increased incidence of myocardial ischaemia. Once again, these data indicate the importance of using inotropes at the minimum effective dose.

Cardiac arrest
Findings from animal studies had long suggested a role for adrenaline in resuscitation prior to the discovery of modern cardiopulmonary resuscitation (CPR) techniques for cardiac arrest (Crule and Dolley, 1960). Later studies suggest vasconstrictor effects of adrenaline may be more important than inotropy in this setting (Paradis et al., 1990; Pearson and Redding, 1963a,b; Yakaitis et al., 1979). In clinical studies, i.v. drug administration following out-of-hospital cardiac arrest was associated with increased short-term survival but not in survival to hospital discharge or improved neurological outcomes. Similarly, comparisons of selective α-adrenergic agonists, vasopressin, high doses of adrenaline/noradrenaline with standard-dose adrenaline do not suggest any differences in survival or neurological outcomes in cardiac arrest (Callaham et al., 1992; Patrick et al., 1995; Woodhouse et al., 1995; Gueugniaud et al., 1998; 2008; Stiell et al., 2001; Perondi et al., 2004; Wenzel et al., 2004; Callaway et al., 2006). Inconsistencies between animal and clinical studies may reflect the validity of laboratory models (Reynolds et al., 2007). Considerable uncertainty remains over the role of vasoactive therapy in cardiac arrest. Current guidelines place greater importance on effective chest compressions, early defibrillation and post-resuscitation care. (Hazinski et al., 2010; Nolan et al., 2010). However, use of adrenaline, particularly in cases of anaphylaxis, is still recommended in the absence of a superior alternative.

Conclusions
Despite widespread use, the evidence base for the use of inotropes and vasopressors in critically ill patients is limited. Clearly, many patients would not survive without inotropic support, but there is, nonetheless, considerable variation in clinical practice. Few large randomized controlled trials directly compare agents in terms of survival or other patient relevant outcomes, which is the level of evidence increasingly demanded by clinicians. However, current practice can be improved through a more detailed understanding of the diverse actions of these agents and the potential toxic effects. It would seem prudent to use minimum necessary doses of such agents until the evidence base improves.

Acknowledgements
RP is a National Institute for Health Research (UK) Clinician Scientist. MB receives salary support from the British Journal of Anaesthesia via a National Institute for Academic Anaesthesia grant.

Conflict of interest
RP is a named inventor on a lapsed patent application relating to a specific use for dopexamine.

References


Inotropes and vasopressors in the critically ill


MN Bangash et al.


Inotropes and vasopressors in the critically ill


Inotropes and vasopressors in the critically ill


